

CLAIM AMENDMENTS

Claims 1 through 11 (canceled)

1 12. (previously presented) A synergistic pharmaceutical
2 composition for treating spasticity which consists essentially of
3 as active ingredients:

4 (a) 40 to 60 parts by weight of tolperisone or eperisone;
5 and

6 (b) 10 parts by weight of dextromethorphan, together with
7 a pharmaceutically acceptable inert carrier.

1 13. (previously presented) The pharmaceutical composi-
2 tion according to claim 12 wherein the active ingredients are 40 to
3 60 parts by weight of tolperisone and 10 parts by weight of
4 dextromethorphan.

1 14. (previously presented) The pharmaceutical composi-
2 tion according to claim 13 wherein a unit of the composition
3 contains 150 mg tolperisone and 30 mg dextromethorphan in admixture
4 with a pharmaceutically acceptable inert carrier.

1 15. (previously presented) The pharmaceutical composi-
2 tion according to claim 12 wherein the unit of the composition

3 includes a pharmaceutically acceptable inert carrier suitable for
4 oral administration.

1 16. (previously presented) A method of treating and/or
2 inhibiting spasticity which comprises the step of administering to
3 a patient in need of said treatment, an anti-spasmodically effec-
4 tive amount of the synergistic pharmaceutical composition defined
5 in claim 12.

1 17. (previously presented) The method of treating and/or
2 inhibiting spasticity defined in claim 16 wherein the pharmaceuti-
3 cal composition is orally administered to the patient in need of
4 said treatment.

1 18. (New) A synergistic anti-allodynic pharmaceutical
2 composition for the treatment of chronic pain, which consists of:
3 (a) 15 parts by weight of tolperisone; and
4 (b) 3 parts by weight of dextromethorphan, together with
5 a pharmaceutically acceptable inert carrier.

1 19. (New) The synergistic anti-allodynic pharmaceutical
2 composition for the treatment of chronic pain defined in claim 18
3 wherein the pharmaceutically acceptable inert carrier is suitable
4 for oral administration.

1 20. (New) An anti-allodynic method of treating or
2 inhibiting chronic pain, which comprises the step of administering
3 to a patient in need of said treatment, an analgesically effective
4 amount of the pharmaceutical composition defined in claim 18.

1 21. (New) An anti-allodynic method of treating or
2 inhibiting chronic pain, which comprises the step of administering
3 to a patient in need of said treatment, an analgesically effective
4 amount of the pharmaceutical composition defined in claim 19.

1 22. (New) A synergistic pharmaceutical composition for
2 treating spasticity and chronic pain, which consists of:

3 (a) 5 to 20 parts by weight of tolperisone; and

4 (b) 1 part by weight of dextromethorphan, together with a
5 pharmaceutically acceptable inert carrier.

1 23. (New) The synergistic pharmaceutical composition for
2 treating spasticity and chronic pain defined in claim 22, which
3 consists of

4 (a) 5 parts by weight of tolperisone; and

5 (b) 1 part by weight of dextromethorphan, together with a
6 pharmaceutically acceptable inert carrier.

1 24. (New) The synergistic pharmaceutical composition for
2 treating spasticity and chronic pain defined in claim 22, which
3 consists of

4 (a) 10 parts by weight of tolperisone; and

5 (b) 1 part by weight of dextromethorphan, together with a
6 pharmaceutically acceptable inert carrier.

1 25. (New) The synergistic pharmaceutical composition for
2 treating spasticity and chronic pain defined in claim 22, which
3 consists of

4 (a) 20 parts by weight of tolperisone; and

5 (b) 1 part by weight of dextromethorphan, together with a
6 pharmaceutically acceptable inert carrier.

1 26. (New) A method of treating spasticity or chronic
2 pain, which comprises the step of administering to a patient in
3 need of said treatment, an analgesically effective amount of the
4 pharmaceutical composition defined in claim 22.

1 27. (New) A synergistic pharmaceutical composition for
2 treating spasticity and chronic pain, which consists of:

3 (a) 25 parts by weight of tolperisone; and

4 (b) .25 to 1 part by weight of dextromethorphan, together
5 with a pharmaceutically acceptable inert carrier.

1 28. (New) A method of treating spasticity or chronic
2 pain, which comprises the step of administering to a patient in
3 need of said treatment, an analgesically effective amount of the
4 pharmaceutical composition defined in claim 27.

1 29. (New) A synergistic pharmaceutical composition for
2 treating spasticity and chronic pain, which consists of:
3 (a) 20 parts by weight of eperisone; and
4 (b) .25 to 1 part by weight of dextromethorphan, together
5 with a pharmaceutically acceptable inert carrier.

1 30. (new) A method of treating spasticity or chronic
2 pain, which comprises the step of administering to a patient in
3 need of said treatment, an analgesically effective amount of the
4 pharmaceutical composition defined in claim 29.